奈玛特韦-利托那韦在晚期肾功能不全合并COVID-19患者中的安全性与有效性
本研究为回顾性匹配队列研究,纳入eGFR 15-30 mL/min/1.73m²且感染COVID-19的退伍军人4020例,其中117例(2.9%)接受奈玛特韦-利托那韦治疗。与未接受奈玛特韦-利托那韦或莫诺拉韦治疗相比,奈玛特韦-利托那韦与急性呼吸衰竭(RR 0.5,95%CI 0.2-0.7)和肺炎(RR 0.6,95%CI 0.3-0.8)风险降低相关,且未发现心血管事件、肝损伤或急性肾损伤风险差异。与莫诺拉韦相比,奈玛特韦-利托那韦未显示心血管事件、急性呼吸衰竭或肺炎风险差异,但与急性肾损伤风险升高相关。
要点
- 晚期肾功能不全患者使用奈玛特韦-利托那韦与急性呼吸衰竭和肺炎风险降低相关。
- 与未治疗相比,奈玛特韦-利托那韦未增加心血管事件、肝损伤或急性肾损伤风险。
- 与莫诺拉韦相比,奈玛特韦-利托那韦与急性肾损伤风险升高相关。
核心结论
- 在晚期肾功能不全合并COVID-19患者中,奈玛特韦-利托那韦与急性呼吸衰竭和肺炎风险降低相关,且与非呼吸系统不良结局无显著差异。
研究设计与样本
- 回顾性匹配队列研究,纳入2022年1月至2023年1月退伍军人健康管理局收治的eGFR 15-30 mL/min/1.73m²且感染COVID-19的患者4020例,其中117例(2.9%)接受奈玛特韦-利托那韦治疗。
主要发现
- 与未接受奈玛特韦-利托那韦或莫诺拉韦治疗相比,奈玛特韦-利托那韦与急性呼吸衰竭风险降低相关(RR 0.5,95%CI 0.2-0.7)。
- 与未治疗相比,奈玛特韦-利托那韦与肺炎风险降低相关(RR 0.6,95%CI 0.3-0.8)。
- 与未治疗相比,奈玛特韦-利托那韦与心血管事件(如心力衰竭 RR 1.0,95%CI 0.7-1.2)、肝损伤(RR 1.2,95%CI 0.7-1.7)或急性肾损伤(RR 1.0,95%CI 0.8-1.2)风险无显著差异。
- 与莫诺拉韦相比,奈玛特韦-利托那韦与急性肾损伤风险升高相关,但心血管事件、急性呼吸衰竭或肺炎风险无显著差异。
临床怎么用
- 对于eGFR 15-30 mL/min/1.73m²的COVID-19患者,可考虑使用奈玛特韦-利托那韦以降低急性呼吸衰竭和肺炎风险,但需监测急性肾损伤。
局限性
- 回顾性分析,研究队列以男性为主。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Nirmatrelvir-ritonavir prevents COVID-19 hospitalization among high-risk adults, but safety concerns limit its use in advanced kidney dysfunction. This study examined safety and effectiveness outcomes from its off-label use in patients with advanced kidney dysfunction. STUDY DESIGN: Retrospective matched cohort study. SETTING & PARTICIPANTS: Patients with estimated glomerular filtration rate (eGFR) 15-30mL/min/1.73m2 and COVID-19 between January 2022 and January 2023 cared for in Veterans Health Administration facilities. EXPOSURE: Treatment with nirmatrelvir-ritonavir, no treatment with nirmatrelvir-ritonavir or molnupiravir, or treatment with molnupiravir. OUTCOME: Incidence of cardiac events, stroke, acute kidney injury, liver injury, hypertension, and infection-related death, respiratory failure, pneumonia, severe infection, and hospitalization within 30-60 days of diagnosis with COVID-19. ANALYTICAL APPROACH: Logistic regression for propensity matching, standardized mean differences for assessment of covariate balance, and conditional logistic regression for estimation of relative risk ratios comparing exposures for each outcome. RESULTS: Among 4,020 patients with an eGFR of 15-30mL/min/1.73m2 and COVID-19, 117 (2.9%) were treated with nirmatrelvir-ritonavir: mean age, 75.6±12.2 (SD) years and eGFR 24.9±4.0 (SD) mL/min/1.73m2. Compared with no treatment with either nirmatrelvir-ritonavir or molnupiravir, treatment with nirmatrelvir-ritonavir was not detectably associated with different risks of cardiovascular events (eg, heart failure: risk ratio [RR], 1.0 [95% CI, 0.7-1.2]; liver injury: RR, 1.2 [95% CI, 0.7-1.7]; or acute kidney injury: RR, 1.0 [95% CI, 0.8-1.2]), but was associated with a lower risk of acute respiratory failure (RR, 0.5 [95% CI, 0.2-0.7]) and pneumonia (RR, 0.6 [95% CI, 0.3-0.8]). Compared with treatment with molnupiravir, treatment with nirmatrelvir-ritonavir was not detectably associated with different risks of cardiovascular events, acute respiratory failure, or pneumonia but was associated with a higher risk of acute kidney injury. Sensitivity analyses among patients with an eGFR of 15-35mL/min/1.73m2 yielded similar findings. LIMITATIONS: Retrospective analysis, predominantly men in the study cohort. CONCLUSIONS: Nirmatrelvir-ritonavir use in the setting of advanced kidney dysfunction was associated with a reduced risk of acute respiratory failure and pneumonia and no detectable differences in non-respiratory adverse outcomes compared with no treatment with either nirmatrelvir-ritonavir or molnupiravir. PLAIN-LANGUAGE SUMMARY: COVID-19 can cause severe complications in patients with advanced kidney disease, yet nirmatrelvir-ritonavir, one of the first-line antiviral therapies, is not recommended in such patients due to safety concerns. We examined its safety and effectiveness among patients with advanced (stage IV) kidney disease. Using Veterans Health Administration records, we compared patients who received nirmatrelvir-ritonavir with those who were not treated with it nor with molnupiravir (a second-line therapy). We also compared treatment with nirmatrelvir-ritonavir with treatment with molnupiravir. We found that nirmatrelvir-ritonavir was associated with a reduced risk of serious lung problems without any evidence of increased risks of heart, liver, or kidney problems compared with not being treated with nirmatrelvir-ritonavir nor molnupiravir. The effectiveness and safety of nirmatrelvir-ritonavir were similar to that of molnupiravir. This study provides real-world evidence supporting nirmatrelvir-ritonavir use for patients with advanced kidney disease.
引用
- Contreras Nieves M, Anand S, Thomas IC, et al. Safety and Effectiveness of Nirmatrelvir-Ritonavir in Patients With Advanced Kidney Dysfunction and COVID-19. Am J Kidney Dis. 2025. PMID: 40204015. doi:10.1053/j.ajkd.2025.02.603
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。